CURILEUM DISCOVERY LTD

Curileum Discovery Ltd is a drug target discovery stage company in London focused on correcting imbalances in cell number and function that underpin serious GI diseases. We target disease at its source rather than treating the outcome of chronic inflammation driving IBD or tumourigenesis in CRC. By altering cell production with drugs at the stem cell or progenitor stage, our approach aims to dampen chronic inflammation allowing for healing of the intestinal barrier in IBD and remove tumourigen... ic cells at an earlier stage. We observe mostly defective, cyst-like crypt organoid structures derived from intestinal mucosal biopsies in Crohn’s disease, ulcerative colitis (UC), and cancer - supporting our working hypothesis that defective stem cells underpin serious GI disorders. In our first year of operation we identified the company’s first novel drug target and are developing a protein-based antagonist drug to reduce chronic inflammation in IBD. In addition to identifying novel drug targets, we are applying our discovery platform to develop innovative tools to monitor the onset, progression, and treatment of IBD and other serious disease, leading to scalable biomarkers to guide clinical development. Curileum provides the discovery and early development pipeline for it's pharmaceutical partners.